

ATTORNEY DOCKET NO. 25006.0001U5  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

**Paul M. Lizardi**

Serial No.: Unassigned

Filed: Concurrently

For: **"ROLLING CIRCLE REPLICATION  
REPORTER SYSTEMS"**

Group Art Unit: 1655

Examiner: Whisenant, E.

J1046 U.S. PTO  
10/038718  
01/02/02

**INFORMATION DISCLOSURE STATEMENT**

BOX PATENT APPLICATION  
Commissioner for Patents  
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.  
Suite 1200, The Candler Building  
127 Peachtree Street, N.E.  
Atlanta, Georgia 30303-1811

January 2, 2002

Sir:

Sir:

Submitted herewith are two copies of form PTO 1449 which were filed in the parent application (Serial No. 09/644,723) with the parent application's docket number, serial number and filing date struck through and those of the present application written in. Each of the references listed on the forms PTO-1449 were either submitted to or cited by the Examiner and are of record in the parent application. Thus, copies are not provided.

Signed in the prosecution of the


Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.

ATTORNEY DOCKET NO. 25006.0001U5  
SERIAL NO.: Unassigned

No fee is believed to be due. However, the Commissioner is hereby authorized to charge any additional fees which may be required, or to credit any overpayment, to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Robert A. Hodges  
Registration No. 41,074


NEEDLE & ROSENBERG, P.C.  
Suite 1200, The Candler Building  
127 Peachtree Street, N.E.  
Atlanta, Georgia 30303-1811  
404/688-0770

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, No. EL 924205961 US in an envelope addressed to: Box Patent Application, Commissioner for Patents, Washington, D.C. 20231, on this 2nd day of January, 2002.

  
Erick Calderon

Date

  
1/2/02

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known			
		Application Number	09/844,725 <i>Unassigned</i>		
		Filing Date	August 23, 2000 <i>Hercwith</i>		
		First Named Inventor	Paul M. Lizardi		
		Group Art Unit			
Examiner Name					
Sheet	1	of	12	Attorney Docket Number	YU 115 CON 121 25006.000145

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		4,883,750		Whiteley, et al.	11-28-1989	
		4,965,188		Mullis et al.	10-23-1990	
		4,994,373		Stavrianopoulos, et al	02-19-1991	
		5,001,050		Blanco et al.	03-19-1991	
		5,198,543		Blanco et al.	03-30-1993	
		5,242,794		Norman, et al.	09-07-1993	
		5,328,824		Ward, et al.	07-12-1994	
		5,354,668		Jeffrey I. Auerbach	10-11-1994	
		5,409,818		Davey et al.	04-25-1995	
		5,455,166		Walker	10-03-1995	
		5,521,065		Whiteley, et al.	05-28-1996	
		5,591,609		Jeffrey I. Auerbach	01-07-1997	
		5,614,389		Jeffrey I. Auerbach	03-25-1997	
		5,714,320		Eric T. Kool	02-03-1998	
		5,733,733		Jeffrey I. Auerbach	03-31-1998	
		5,854,033		Lizardi	12-29-1998	

U.S. PTO

10/038718

01/02/02

J1046 U.S. PTO  
 10/038718  
 01/02/02

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		WO	92/01813		Syngene, Inc.	02-16-1992		
		WO	94/24312		Beckman Instruments, Inc.	10-27-1994		
		WO	95/03432		Bio-Rad Laboratories, Inc.	02-02-1995		
		WO	95/22623		Landegren, Ulf	12-24-1995		

Examine Signature		Date Considered	
-------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	09/644,723 <i>Unassigned</i>
				Filing Date	August 23, 2000 <i>Heredith</i>
				First Named Inventor	Paul M. Lizardi
				Group Art Unit	
				Examiner Name	
Sheet	2	of	12	Attorney Docket Number	YU 115 CON (2) 25006.0001US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		WO	95/35390		Mount Sinai School of Medicine of the City University of New York	12-28-1995		
		WO	97/20948		Hofman-Bang & Boutard, Lehmann & Ree	06-12-1997		
		WO	97/42346		Tepnel Medical Limited	11-13-1997		
		EP	0 128 332	A2	Enzo Biochem, Inc.	12-19-1984		
		EP	0 356 021	A2	Imperial Chemical Industries PLC	02-28-1990		
		EP	0 439 182	B1	Abbott Laboratories	07-31-1991		
		EP	0 505 012	A2	F. Hoffmann-La Roche, AG	09-23-1992		
		EP	0 667 393	A2	Enzo Diagnostics, Inc.	08-16-1995		
		JP	4262799		Toyobo Co. LTD.	09-18-1992		
		JP	4304900		Toyobo Co. LTD.	10-28-1992		
		AU	649066		Syngene, Inc.	05-12-1994		

Examine Signature		Date Considered	
-------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box ->



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	<del>09/644,723</del> <b>Unassigned</b>		
		Filing Date	<b>August 23, 2000</b> <b>Herewith</b>		
		First Named Inventor	<b>Paul M. Lizardi</b>		
		Group Art Unit			
		Examiner Name			
Sheet	<b>3</b>	of	<b>12</b>	Attorney Docket Number	<b>YU 115 CON (2) 2500.0001 US</b>

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ABRAVAYA, et al., "Detection of point mutations with a modified ligase chain reaction (Gap-LCR)", <i>Nucleic Acids Res.</i> 23(4): 675-682 (1995).	
		ALIOTTA, et al., "Thermostable Bst DNA polymerase lacks a 3'-5' proofreading exonuclease activity," <i>Genet. Anal.</i> 12:185-195 (1996).	
		ALVES & CARR, "Dot blot detection of point mutations with adjacently hybridising synthetic oligonucleotide probes", <i>Nucleic Acids Res.</i> 16(17): 8723 (1988).	
		ARNOLD, et al., "Assay Formats Involving Acridinium-Ester-Labeled DNA Probes", <i>Clin. Chem.</i> 35(8): 1588-1594 (1989).	
		BARANY, "Genetic disease detection and DNA amplification using cloned thermostable ligase", <i>Proc. Natl. Acad. Sci. USA</i> 88: 189-193 (1991).	
		BERTINA, et al., "Mutation in blood coagulation factor V associated with resistance to activated protein C", <i>Nature</i> 369: 64-67 (1994).	
		BIRKENMEYER & MUSHAHWAR, "DNA probe amplification methods", <i>Journal of Virological Methods</i> 35: 117-126 (1991).	
		BLANCO & SALAS, "Characterization and purification of a phage ø29-encoded DNA polymerase required for the initiation of replication", <i>Proc. Natl. Acad. Sci. USA</i> 81: 5325-5329 (1984).	
		BLANCO, et al., "Highly Efficient DNA Synthesis by the Phage ø29 DNA Polymerase", <i>Journal of Biological Chemistry</i> 264(15): 8935-8940 (1989).	
		BLANCO, et al., "Terminal protein-primed DNA amplification", <i>Proc. Natl. Acad. Sci. USA</i> 91: 12198-12202 (1994).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-95)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known			
		Application Number	09/644,729 <i>Unassigned</i>		
		Filing Date	August 23, 2000 <i>Hercowitz</i>		
		First Named Inventor	Paul M. Lizardi		
		Group Art Unit			
		Examiner Name			
Sheet	4	of	12	Attorney Docket Number	YU 115 CON (2) 2000.0001US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		BOEHMER & LEHMAN, "Herpes Simplex Virus Type 1 ICP8: Helix-Destabilizing Properties", <i>Journal of Virology</i> 67(2): 711-715 (1993).	
		BROUDE, et al., "Enhanced DNA sequencing by hybridization", <i>Proc. Natl. Acad. Sci. USA</i> 91: 3072-3076 (1994).	
		BURGESS & JACUTIN, "A new photolabile protecting group for nucleotides" <i>Am. Chem. Soc. Abstracts</i> , volume 221, abstract 281 (1996).	
		BUTLER & CHAMBERLIN, "Bacteriophage SP6-specific RNA Polymerase", <i>Journal of Biological Chemistry</i> 257: 5772-5778 (1982).	
		CHATTERJEE, et al., "Cloning and overexpression of the gene encoding bacteriophage T5 DNA polymerase", <i>Gene</i> 97: 13-19 (1991).	
		CHETVERINA, et al., "Cloning of RNA molecules in vitro," <i>Nucleic Acids Research</i> 21:2349-2353 (1993).	
		DAUBENDIEK, et al., "Generation of catalytic RNAs by rolling transcription of synthetic DNA nanocircles," <i>Nature Biotechnology</i> 15:273-277 (1997).	
		DAUBENDIEK, et al., "Rolling-Circle RNA Synthesis: Circular Oligonucleotides as Efficient Substrates for T7 RNA Polymerase," <i>J. Am. Chem. Soc.</i> 117:7818-7819 (1995).	
		DAVANLOO, et al., "Cloning and expression of the gene for bacteriophage T7 RNA polymerase", <i>Proc. Natl. Acad. Sci. USA</i> 81: 2035-2039 (1984).	
		DYNAL, Technical Handbook, "Biomagnetic Techniques in Molecular Biology" (DYNAL A.S., 1995).	

Examiner's Signature	Date Considered
-------------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	09/044,725 <sup>1</sup> Unassigned
		Filing Date	August 29, 2000 Herewith
		First Named Inventor	Paul M. Lizardi
		Group Art Unit	
		Examiner Name	
Sheet 5 of 12	Attorney Docket Number	YU 115 CON (2) 2500-0001 US	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ERNST, et al., "Cyanine dye labeling reagents for sulfhydryl groups" <i>Cytometry</i> 10:3-10 (1989).	
		FIRE & XU, "Rolling replication of short DNA circles", <i>Proc. Natl. Acad. Sci. USA</i> 92: 4641-4645 (1995).	
		GASPARRO, et al., "Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: characterization of psoralen monoadduct and crosslink formation" <i>Nucleic Acids Research</i> 22(14): 2845-2852 (1994).	
		GERDES, et al., "Dynamic changes in the higher-level chromatin organization of specific sequences revealed by in situ hybridization in nuclear halos," <i>J. Cell Biol.</i> 126:289-304 (1994).	
		GUNJI, et al., "Correlation Between the Serum Level of Hepatitis C Virus RNA and Disease Activities in Acute and Chronic Hepatitis C", <i>Int. J. Cancer</i> 52(5): 726-730 (1992).	
		GUO, et al., "Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports", <i>Nucleic Acids Res.</i> 22(24): 5456-5465 (1994).	
		GUO, et al., "Enhanced discrimination of single nucleotide polymorphisms by artificial mismatch hybridization," <i>Nature Biotechnology</i> 15:331-335 (1997).	
		GUPTA, et al., "Ninth International Conference on AIDS/Fourth STD World Congress", June 6-11, 1993, Berlin, Germany.	
		HACIA, et al., "Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-color fluorescence analysis," <i>Nature Genetics</i> 14:441-447.	
		HAGIWARA, et al., "Quantitation of hepatitis C Virus RNA in Serum of Asymptomatic Blood Donors and Patients with Type C Chronic Liver Disease", <i>Hepatology</i> 17(4): 545-550 (1993).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known			
		Application Number	<del>09/644,723</del> <b>Unassigned</b>		
		Filing Date	<b>August 23, 2000</b> <b>Neurath</b>		
		First Named Inventor	Paul M. Lizardi		
		Group Art Unit			
		Examiner Name			
Sheet	6	of	12	Attorney Docket Number	<del>YU 115 CON (2)</del> <b>2500.0001 US</b>

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		HANVEY, et al., "Antisense and Antigene Properties of Peptide Nucleic Acids", <i>Science</i> 258: 1481-1485 (1992).	
		HATA, et al., "Structure of the Human Ornithine Transcarbamylase Gene", <i>J. Biochem.</i> 103: 302-308 (1988).	
		HENDRICKSON, et al., "High sensitivity multianalyte immunoassay using covalent DNA-labeled antibodies and polymerase chain reaction", <i>Nucleic Acids Res.</i> 23(3): 522-529 (1995).	
		HOLLOWAY, et al., "An exonuclease-amplification coupled capture technique improves detection of PCR product", <i>Nucleic Acids Research</i> 21: 3905-3906 (1993).	
		HOY & SCHIMKE, "Bromodeoxyuridine/DNA analysis of replication in CHO cells after exposure to UV light", <i>Mutation Research</i> 290: 217-230 (1993).	
		HSUIH, et al., "Quantitative Detection of HCV RNA Using Novel Ligation-Dependent Polymerase Chain Reaction", <i>American Association for the Study of Liver Diseases</i> ; (Chicago, IL, November 3-7, 1995) [poster abstract].	
		ITAKURA, et al., "Synthesis and Use of Synthetic Oligonucleotides", <i>Annual Review of Biochemistry</i> 53: 323-356 (1984).	
		JACOBSEN, et al., "The N-Terminal Amino-Acid Sequences of DNA Polymerase I from <i>Escherichia coli</i> and of the Large and the Small Fragments Obtained by a Limited Proteolysis", <i>Eur. J. Biochem.</i> 45: 623-627 (1974).	
		JOHNSTONE & THORPE, <i>Immunochemistry In Practice</i> (Blackwell Scientific Publications, Oxford, England, 1987) pages 209-216 and 241-242	
		JUNG, et al., "Bacteriophage PRD1 DNA polymerase: Evolution of DNA polymerases", <i>Proc. Natl. Acad. Sci. USA</i> 84: 8287 (1987).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	09/644,723 Unassigned
		Filing Date	August 23, 2000 Herewith
		First Named Inventor	Paul M. Lizardi
		Group Art Unit	
		Examiner Name	
Sheet 7 of 12	Attorney Docket Number	YU 115 CON (2) 2500-000105	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		KABOORD & BENKOVIC, "Accessory proteins function as matchmakers in the assembly of the T4 DNA polymerase holoenzyme", <i>Current Biology</i> 5: 149-157 (1995).	
		KALIN, et al., "Evaluation of the ligase chain reaction (LCR) for the detection of point mutations", <i>Mutation Research</i> 283(2): 119-123 (1992).	
		KAPLAN, et al., "Rapid photolytic release of adenosine 5'-triphosphate from a protected analogue: utilization by the Na:K pump of human red blood cell ghosts" <i>Biochem.</i> 17:1929-1935 (1978).	
		KELLOGG, et al., "TaqStart Antibody™: "Hot Start" PCR Facilitated by a Neutralizing Monoclonal Antibody Directed Against Taq DNA Polymerase", <i>BioTechniques</i> 16(6): 1134-1137 (1994).	
		KERKHOF, "A Comparison of Substrates for Quantifying the Signal from a Nonradiolabeled DNA Probe", <i>Analytical Biochemistry</i> 205: 359-364 (1992).	
		KHRAPKO, et al., "Hybridization of DNA with Oligonucleotides Immobilized in Gel: A Convenient Method for Detecting Single Base Substitutions", <i>Molecular Biology (Mosk) (USSR)</i> 25: 718-730 (1991).	
		KING, et al., "Bridging the Gap", <i>Journal of Biological Chemistry</i> 269(18): 13061-13064 (1994).	
		KONG, et al., "Characterization of a DNA Polymerase from the Hyperthermophile Archaea <i>Thermococcus litoralis</i> ", <i>Journal of Biological Chemistry</i> 268: 1965-1975 (1993).	
		KOOL, "Circular Oligonucleotides: New Concepts in Oligonucleotide Design," <i>Annual Rev. Biomol. Struct.</i> 25:1-28 (1996).	
		KUNKEL, et al., "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection", <i>Methods in Enzymology</i> 154: 367-382 (1987).	

Examiner's Signature	Date Considered
-------------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known			
		Application Number	<del>69/644,722</del> Unassigned		
		Filing Date	<del>August 23, 2000</del> November		
		First Named Inventor	Paul M. Lizardi		
		Group Art Unit			
		Examiner Name			
Sheet	8	of	12	Attorney Docket Number	YU 115 CON (2) 2,500,000 US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		LAMTURE, et al., "Direct detection of nucleic acid hybridization on the surface of a charge coupled device" <i>Nucleic Acids Research</i> 22(11): 2121-2125 (1994).	
		LANDEGREN, "Molecular mechanics of nucleic acid sequence amplification," <i>Trends Genetics</i> 9:199-202 (1993).	
		LANDEGREN, et al., "A Ligase-Mediated Gene Detection Technique", <i>Science</i> 241: 1077-1080 (1988).	
		LANGER, et al., "Enzymatic synthesis of biotin-labeled polynucleotides: Novel nucleic acid affinity probes", <i>Proc. Natl. Acad. Sci. USA</i> 78(11): 6633-6637 (1981).	
		LAWYER, et al., "High-level Expression, Purification, and Enzymatic Characterization of Full-length <i>Thermus aquaticus</i> DNA Polymerase and a Truncated Form Deficient in 5' to 3' Exonuclease Activity", <i>PCR Methods Applications</i> 2(4): 275-287 (1993).	
		LEFRERE, et al., "Towards a new predictor of AIDS progression through the quantitation of HIV-1 DNA copies by PCR in HIV-infected individuals", <i>British Journal of Haematology</i> 82(2): 467-471 (1992).	
		LESNICK & FREIER, "Relative Thermodynamic Stability of DNA, RNA, and DNA:RNA Hybrid Duplexes: Relationship with Base Composition and Structure", <i>Biochemistry</i> 34: 10807-10815 (1995).	
		LIU, et al., "Rolling circle DNA synthesis: Small circular oligonucleotides as efficient templates for DNA polymerases," <i>J. Am. Chem. Soc.</i> 118:1587-1594 (1996).	
		LOCKHART, et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays," <i>Nature Biotechnology</i> 14:1675-1680 (1996).	
		LU, et al., "High Concentration of Peripheral Blood Mononuclear Cells Harboring Infectious Virus Correlates with Rapid Progression of Human Immunodeficiency Virus Type 1-Related Diseases", <i>JID</i> 168(5): 1165-8116 (1993).	

Examiner's Signature	Date Considered
-------------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/644,729 <i>Unassigned</i>		
		Filing Date	August 23, 2000 <i>Herewith</i>		
		First Named Inventor	Paul M. Lizardi		
		Group Art Unit			
		Examiner Name			
Sheet	9	of	12	Attorney Docket Number	YU 115 CON (2) 2,5206.000145

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		LUKYANOV, et al., "Molecule by molecule PCR amplification of complex DNA mixtures for direct sequencing: an approach to in vitro cloning," <i>Nucleic Acids Research</i> 20:1691-1696 (1996).	
		LUO, et al., "Improving the fidelity of <i>Thermus thermophilus</i> DNA ligase," <i>Nucl. Acids Res.</i> 24:3071-3078 (1996).	
		MARSHALL, et al., "Detection of HCV RNA by the Asymmetric Gap Ligase Chain Reaction", <i>PCR Methods and Applications</i> 4: 80-84 (1994).	
		MASKOS, et al., "Oligonucleotide hybridizations on glass supports: a novel linker for oligonucleotides synthesized <i>in situ</i> ," <i>Nucleic Acids Research</i> 20:1679-1684 (1992).	
		MATSUMOTO, et al., "Primary structure of bacteriophage M2 DNA polymerase: conserved segments within protein-priming DNA polymerases and DNA polymerase I of <i>Escherichia coli</i> , <i>Gene</i> 84(2): 247-255 (1989).	
		MCCRAY, et al., "A new approach to time-resolved studies of ATP-requiring biological systems: Laser flash photolysis of caged ATP" <i>Proc. Natl. Acad. Sci. USA</i> 77:7237-7241 (1980).	
		MCGRAW, et al., "Sequence-dependant oligonucleotide-target duplex stabilities: rules from empirical studies with a set of twenty-mers" <i>Biotechniques</i> 8:674-678 (1990).	
		MELTON, et al., "Efficient <i>in vitro</i> synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter", <i>Nucleic Acids Research</i> 12(18): 7035-7056 (1984).	
		METZKER, et al., "Termination of DNA synthesis by novel 3'-modified-deoxyribonucleoside 5'-triphosphates" <i>Nucleic Acids Research</i> 22:4259-4267 (1994).	
		MUJUMDAR, et al., "Cyanine dye labeling reagents containing isothiocyanate groups" <i>Cytometry</i> 10:11-19 (1989).	

Examiner's Signature	Date Considered
-------------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known			
		Application Number	<del>09/644,723</del> Unassigned		
		Filing Date	August 23, 2000 <i>Herewith</i>		
		First Named Inventor	Paul M. Lizardi		
		Group Art Unit			
		Examiner Name			
Sheet	10	of	12	Attorney Docket Number	<del>WU 115 CON (2)</del> 25006.000145

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		NARANG, et al., "Chemical Synthesis of Deoxyoligonucleotides by the Modified Triester Method", <i>Methods Enzymology</i> 65: 610-620 (1980).	
		NEWTON, et al., "Analysis of any point mutation in DNA. The amplification refractory mutation refractory mutation system (ARMS)," <i>Nucl. Acids Res.</i> 17:2503-2516 (1989).	
		NIELSEN, et al., "Peptide Nucleic Acid (PNA). A DNA Mimic with a Peptide Backbone", <i>Bioconjugate Chemistry</i> , 5: 3-7 (1994).	
		NIELSEN, et al., "Peptide nucleic acids (PNAs): Potential anti-sense and anti-gene agents", <i>Anti-Cancer Drug Design</i> , 8: 53-63 (1993).	
		NIKIFOROV, et al., "Genetic Bit Analysis: a solid phase method for typing single nucleotide polymorphisms", <i>Nucleic Acids Research</i> 22(20): 4167-4175 (1994).	
		NIKIFOROV, et al., "The Use of Phosphorothioate Primers and Exonuclease Hydrolysis for the Preparation of Single-stranded PCR Products and their Detection by Solid-phase Hybridization", <i>PCR Methods and Applications</i> 3: 285-291 (1994).	
		NILSSON, et al., "Padlock Probes: Circularizing Oligonucleotides for Localized DNA Detection", <i>Science</i> 265: 2085-2088 (1994).	
		NILSSON, et al., "U. Padlock probes reveal single-nucleotide differences, parent of origin and <i>in situ</i> distribution of centromeric sequences in human chromosomes 13 and 21," <i>Nature Genet.</i> 16:252-255 (1997).	
		ØRUM, et al., "Single base pair mutation analysis by PNA directed PCR clamping", <i>Nucleic Acids Research</i> 21(23): 5332-5336 (1993).	
		PANASNKO, et al., "A Simple, Three-Step Procedure for the Large Scale Purification of DNA Ligase from a Hybrid λ Lysogen Construction <i>in Vitro</i> , <i>Journal Biological Chemistry</i> 253: 4590-4592 (1978).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	<del>09/644,723</del> Unassigned
		Filing Date	August 23, 2000 - Newwith
		First Named Inventor	Paul M. Lizardi
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	YU 115 CON (2) 2500.00045
Sheet	11	of	12

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		PEASE, et al., "Light-generated oligonucleotide arrays for rapid DNA sequence analysis", <i>Proc. Natl. Acad. Sci. USA</i> 91(11): 5022-5026 (1994).	
		PIATAK, et al., "High Levels of HIV-1 in Plasma During All Stages of Infection Determined by Competitive PCR", <i>Science</i> 259(5102): 1749-1754 (1993).	
		PILLAI, et al., "Photoremovable protecting groups in organic synthesis" <i>Synthesis</i> 1-26 (1980).	
		POKROVSKAYA & GUREVICH, "In Vitro Transcription: Preparative RNA Yields in Analytical Scale Reactions", <i>Analytical Biochemistry</i> 220: 420-423 (1994).	
		PRAKASH, et al., "Structural effects in the recognition of DNA by circular oligonucleotides," <i>J. Amer. Chem. Soc.</i> 114:3523-3527 (1992).	
		RICHARDS, et al., "Conditional mutator phenotypes in hMS2H2-deficient tumor cell lines," <i>Science</i> 277:1523-1526 (1997).	
		RIED, et al., "Simultaneous visualization of seven different DNA probes by <i>in situ</i> hybridization using combinatorial fluorescence and digital imaging microscopy", <i>Proc. Natl. Acad. Sci. USA</i> 89(4): 1388-1392 (1982).	
		RIGLER & ROMANO, "Differences in the Mechanism of Stimulation of T7 DNA Polymerase by Two Binding Modes of <i>Escherichia coli</i> Single-stranded DNA-binding Protein", <i>Journal of Biological Chemistry</i> , 270(15): 8910-8919 (1995).	
		RYCHLIK, et al., "Optimization of the annealing temperature for DNA amplification <i>in vitro</i> ", <i>Nucleic Acids Research</i> 18(21): 6409-6412 (1990).	
		RYS & PERSING, "Preventing False Positives: Quantitative Evaluation of Three Protocols for Inactivation of Polymerase Chain Reaction Amplification Products", <i>Journal of Clinical Microbiology</i> 31(9): 2356-2360 (1993).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box ->



PTO/SB/08A (10-96)  
Approved for use through 10/31/99, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known			
		Application Number	<del>09/644,723</del> Unassigned		
		Filing Date	August 23, 2000 - Herewith		
		First Named Inventor	Paul M. Lizardi		
		Group Art Unit			
		Examiner Name			
Sheet	12	of	12	Attorney Docket Number	YU 115 CON (2) 25006.000145

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		SAKSELA, et al., "Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4 <sup>+</sup> lymphocytes", <i>Proc. Natl. Acad. Sci. USA</i> 91(3): 1104-1108 (1994).	
		SAMBROOK, et al., "Molecular Cloning: A Laboratory Manual, Second Edition" ( <i>Cold Spring Harbor Laboratory Press</i> , Cold Spring Harbor, N.Y., 1989 (Chapters 5, 6)).	
		SARIS, et al., "Blotting of RNA into RNA exchange paper allowing subsequence characterization by in situ translation in addition to blot hybridization," <i>Nucleic Acids Res.</i> 10:4831-4843 (1982).	
		SCHEMA, et al., "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray" <i>Science</i> 270:467-470 (1995).	
		SCHEMA, et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci. USA</i> 91:10614-10619 (1994).	
		SCHENBORN & MEIRENDORF, "A novel transcription property of SP6 and 17 RNA polymerases: dependence on template structure", <i>Nucleic Acids Research</i> 13(17): 6223-6236 (1985).	
		SCHWARZ, "Improved yields of long PCR products using gene 32 protein," <i>Nucl. Acids Res.</i> 18:1079 (1990).	
		SIEGEL, et al., "A Novel DNA Helicase from Calf Thymus", <i>Journal of Biological Chemistry</i> 267(19): 13629-13635 (1992).	
		SKALITER & LEHMAN, "Rolling circle DNA replication <i>in vitro</i> by a complex of herpes simplex virus type 1-encoded enzymes", <i>Proc. Natl. Acad. Sci. USA</i> 91(22): 10665-10669 (1994).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+